HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.

AbstractBACKGROUND:
Aromatase inhibitors are widely employed in the adjuvant treatment of early stage breast cancer. The impact of aromatase inhibitors has not been established in ethnic minority women.
PATIENTS AND METHODS:
The purpose of this study was to evaluate the impact of letrozole on minority women in MA.17, a placebo-controlled trial of letrozole following 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Retrospective comparison of disease-free survival (DFS), side effects, and mean changes in quality of life (QOL) scores from baseline between Caucasian and minority women was performed.
RESULTS:
Minority (n = 352) and Caucasian (n = 4708) women were analyzed. There was no difference between these groups in DFS (91.6% versus 92.4% respectively for 4 year DFS). Letrozole, compared with placebo, significantly improved DFS for Caucasians (HR = 0.55; P < 0.0001) but not for minorities (HR = 1.39; P = 0.53). Among women who received letrozole, minorities had a significantly lower incidence of hot flashes (49% versus 58%; P = 0.02), fatigue (29% versus 39%; P = 0.005), and arthritis (2% versus 7%; P = 0.006) compared with Caucasians. Mean change in QOL scores for minority women who received letrozole demonstrated improved mental health at the 6-month assessment (P = 0.02) and less bodily pain at the 12-month assessment (P = 0.046).
CONCLUSION:
Letrozole improved DFS in Caucasians but a definite benefit in minority women has not yet been demonstrated. Minority women tolerated letrozole better than Caucasians in terms of toxicity. These results need confirmation in other trials of aromatase inhibitors.
AuthorsB Moy, D Tu, J L Pater, J N Ingle, L E Shepherd, T J Whelan, P E Goss
JournalAnnals of oncology : official journal of the European Society for Medical Oncology / ESMO (Ann Oncol) Vol. 17 Issue 11 Pg. 1637-43 (Nov 2006) ISSN: 0923-7534 [Print] England
PMID16936184 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Nitriles
  • Triazoles
  • Tamoxifen
  • letrozole
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal (administration & dosage, therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols
  • Aromatase Inhibitors (administration & dosage, therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Comorbidity
  • Disease-Free Survival
  • Ethnic Groups
  • European Continental Ancestry Group
  • Female
  • Humans
  • Mental Health
  • Middle Aged
  • Minority Groups
  • Nitriles (administration & dosage, adverse effects, therapeutic use)
  • Pain
  • Patient Compliance
  • Postmenopause (physiology)
  • Tamoxifen (administration & dosage, therapeutic use)
  • Treatment Outcome
  • Triazoles (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: